Information Provided By:
Fly News Breaks for August 22, 2017
PCRX
Aug 22, 2017 | 08:37 EDT
Needham analyst Serge Belanger started coverage of Pacira with a $55 price target and a Buy rating. He says that data indicate that the company's non-opioid pain treatment has a :"compelling" growth outlook. The analyst thinks that the company's sales will rise as soon as 2H17, and he believes that the decline in the stock has created an attractive entry point.
News For PCRX From the Last 2 Days
There are no results for your query PCRX